Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment-Reference-Cited by-同舟云学术

Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment

Published:2016-11-22 Issue:5 Volume:57 Page:584-591
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Katsube Takayuki¹,Echols Roger²,Arjona Ferreira Juan Camilo²,Krenz Heidi K.²,Berg Jolene Kay³,Galloway Christopher⁴

Affiliation:

1. Shionogi & Co, Ltd Osaka Japan

2. Shionogi Inc Florham Park NJ USA

3. DaVita Clinical Research Minneapolis MN USA

4. DaVita Clinical Research Lakewood CO USA

Funder

Shionogi

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.841

Reference20 articles.

1. Siderophore–drug complexes: potential medicinal applications of the ‘Trojan horse’ strategy

2. In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria

3. In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

4. ItoA TobaS NishikawaT et al.S‐649266 a novel siderophore cephalosporin: binding affinity to PBP and in vitro bactericidal activity. Presented at 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2015); April 25‐28 2015; Copenhagen. Poster P0250.

5. NakamuraR TobaS TsujiM YamanoY ShimadaJ.A novel siderophore cephalosporin: IV. In vivo efficacy in various murine infection models. Presented at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014); September 5‐9 2014; Washington DC. Poster F‐1558.

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old With Infections Treated With Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study;Pediatric Infectious Disease Journal;2024-09-04

2. Cefiderocol: a first and novel class of siderophore cephalosporin for Carbapenem-resistant Gram-negative infection;Folia Pharmacologica Japonica;2024-09-01

3. Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach;Pharmacology Research & Perspectives;2024-08-23

4. In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol;The Journal of Antibiotics;2024-07-30

5. Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model;HEALTH TECHNOL ASSES;2024